Finland Fimea · August 21, 2026

Fimea assessment report on datopotamab deruxtecan for advanced hormone receptor-positive HER2-negative breast cancer

Original title: Fimea on julkaissut arviointiraportin datopotamabi-derukstekaanin vaikutuksista edenneen hormonireseptoripositiivisen HER2-negatiivisen rintasyövän hoidossa

Fimea published an assessment report on the efficacy and safety of datopotamab deruxtecan for advanced hormone receptor-positive HER2-negative breast cancer.

Low obligation Product class Pharmaceuticals Finland Pharmaceuticals
Read the official source ↗

Published by Finland Fimea. HealthSignal links to the original document; the summary above is extracted from the source text.